1039356-95-0 Usage
Description
3-ForMyliMidazo[1,5-a]pyridine-1-carboxylic acid, also known as FMP-1, is a fused heterocyclic chemical compound with a pyridine ring and a carboxylic acid group. It has potential applications in medicinal chemistry and drug development due to its promising properties as an anticancer, anti-inflammatory, and antioxidant agent.
Uses
Used in Pharmaceutical Industry:
3-ForMyliMidazo[1,5-a]pyridine-1-carboxylic acid is used as an anticancer agent for its potential ability to inhibit the growth of cancer cells. It is being studied for its effectiveness in treating various types of cancer.
Used in Anti-inflammatory Applications:
3-ForMyliMidazo[1,5-a]pyridine-1-carboxylic acid is used as an anti-inflammatory agent for its potential to alleviate inflammation and related symptoms in various conditions.
Used in Antioxidant Applications:
3-ForMyliMidazo[1,5-a]pyridine-1-carboxylic acid is used as an antioxidant agent for its potential to combat oxidative stress and protect against oxidative stress-related diseases.
Further research is needed to fully understand the biological activities and potential therapeutic uses of 3-ForMyliMidazo[1,5-a]pyridine-1-carboxylic acid in these applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1039356-95-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,9,3,5 and 6 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1039356-95:
(9*1)+(8*0)+(7*3)+(6*9)+(5*3)+(4*5)+(3*6)+(2*9)+(1*5)=160
160 % 10 = 0
So 1039356-95-0 is a valid CAS Registry Number.
1039356-95-0Relevant articles and documents
Imidazopyridine CB2 agonists: Optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy
Trotter, B. Wesley,Nanda, Kausik K.,Burgey, Christopher S.,Potteiger, Craig M.,Deng, James Z.,Green, Ahren I.,Hartnett, John C.,Kett, Nathan R.,Wu, Zhicai,Henze, Darrell A.,Penna, Kimberly Della,Desai, Reshma,Leitl, Michael D.,Lemaire, Wei,White, Rebecca B.,Yeh, Suzie,Urban, Mark O.,Kane, Stefanie A.,Hartman, George D.,Bilodeau, Mark T.
, p. 2354 - 2358 (2011/06/17)
A new series of imidazopyridine CB2 agonists is described. Structural optimization improved CB2/CB1 selectivity in this series and conferred physical properties that facilitated high in vivo exposure, both centrally and peripherally. Administration of a h
